Discover 1,005 paid clinical trials in Minneapolis, Minnesota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Minneapolis currently offers various active clinical trials with a focus on many chronic conditions, including asthma, arthritis, kidney disease, and hidradenitis suppurativa. The city’s leading healthcare institutions are recruiting participants to take part in paid research studies as healthy volunteers, as well as those looking for studies targeting specific health issues, providing access to innovative treatments and contributing to the development of new therapies.
Filter
2
Filter results
Results: 1,005
Active & Responsive
Effect of Vibro-tactile Stimulation Intensity on Head Posture in Cervical Dystonia
for
Cervical Dystonia
Location: Minneapolis MN
Sponsor: University of Minnesota
Sex: All
Age: 30+
Code: NCT07245615
Recruiting
Active & Responsive
Evaluation of Accuracy of the Owlet OSS 3.0 Sensor in the Neonatal Population
for
Pulse Oximeter Validation
Location: Minneapolis MN, Birmingham AL
Sponsor: Owlet Baby Care, Inc.
Sex: All
Age: 0
Code: NCT06771206
Recruiting
Active & Responsive
A Natural History Study of the Gangliosidoses
for
Tay-Sachs Disease, Sandhoff Disease,
Location: Minneapolis MN
Sponsor: University of Minnesota
Sex: All
Age: 0+
Code: NCT00668187
Recruiting
Active & Responsive
Feasibility of Identifying Brain Mechanisms of Qigong and Behavioral Outcomes After Qigong Practice in People With Chronic Low Back Pain
for
Low Back Pain
Location: Minneapolis MN
Sponsor: University of Minnesota
Sex: All
Age: 18 - 70
Code: NCT04164225
Recruiting
Active & Responsive
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
for
Niemann-Pick Type C Disease
Location: Minneapolis MN, Rochester MN, Dallas TX, Fairfax VA,
Sponsor: Azafaros B.V.
Sex: All
Age: 4+
Code: NCT07082725
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
for
High-Risk Neuroblastoma
Location: Minneapolis MN, Chicago IL, Toronto, Aurora CO,
Sponsor: Renaissance Pharma Ltd.
Sex: All
Age: 1 - 18
Code: NCT07549321
Phase 2, Phase 3, Recruiting
Active & Responsive
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
for
Cytomegalovirus Prophylaxis
Location: Minneapolis MN, Rochester MN, Chicago IL, Ann Arbor MI,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 0 - 17
Code: NCT07199465
Phase 1, Recruiting
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Sponsor: Masonic Cancer Center, University of Minnesota
Sex: All
Age: 18+
Code: NCT07541573
Phase 1, Recruiting
Active & Responsive
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
for
Acute Myeloid Leukemia, TP53
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota
Sex: All
Age: 18+
Code: NCT07008638
Phase 1, Phase 2, Recruiting
Active & Responsive
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
for
Bone Pain, Metastatic Malignant Neoplasm in the Bone,
Location: Minneapolis MN, Atlanta GA, Philadelphia PA,
Sponsor: University of Southern California
Sex: All
Age: 18+
Code: NCT03858205
Recruiting
Active & Responsive
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
for
Severe Aplastic Anemia,
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota
Sex: All
Age: 0 - 70+
Code: NCT06412497
Phase 2, Recruiting
Active & Responsive
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies